151 related articles for article (PubMed ID: 22054111)
1. Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.
Costantini A; Marinelli K; Biagioni G; Monachetti A; Ferreri ML; Butini L; Montroni M; Manzin A; Bagnarelli P
BMC Infect Dis; 2011 Nov; 11():310. PubMed ID: 22054111
[TBL] [Abstract][Full Text] [Related]
2. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients.
Amponsah-Dacosta E; Selabe SG; Mphahlele MJ
J Med Virol; 2018 Feb; 90(2):291-303. PubMed ID: 28971485
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
Calisti G; Muhindo R; Boum Y; Wilson LA; Foster GM; Geretti AM; Bhagani S
Trans R Soc Trop Med Hyg; 2015 Nov; 109(11):723-9. PubMed ID: 26386408
[TBL] [Abstract][Full Text] [Related]
6. Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus.
Huang YS; Sun HY; Chang SY; Chuang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2022; 60(5-6):106682. PubMed ID: 36279976
[TBL] [Abstract][Full Text] [Related]
7. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features.
Morsica G; Ancarani F; Bagaglio S; Maracci M; Cicconi P; Cozzi Lepri A; Antonucci G; Bruno R; Santantonio T; Tacconi L; Baldelli F; Piscopo R; Santoro D; Lazzarin A; D'Arminio Monforte A;
Infection; 2009 Oct; 37(5):445-9. PubMed ID: 19669092
[TBL] [Abstract][Full Text] [Related]
8. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
Soriano V; Mocroft A; Peters L; Rockstroh J; Antunes F; Kirkby N; de Wit S; Monforte Ad; Flisiak R; Lundgren J;
J Antimicrob Chemother; 2010 Mar; 65(3):548-55. PubMed ID: 20051475
[TBL] [Abstract][Full Text] [Related]
9. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients.
Pogány K; Zaaijer HL; Prins JM; Wit FW; Lange JM; Beld MG
AIDS Res Hum Retroviruses; 2005 Nov; 21(11):922-6. PubMed ID: 16386107
[TBL] [Abstract][Full Text] [Related]
10. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
Coffin CS; Mulrooney-Cousins PM; Osiowy C; van der Meer F; Nishikawa S; Michalak TI; van Marle G; Gill MJ
J Clin Virol; 2014 Aug; 60(4):347-53. PubMed ID: 24881491
[TBL] [Abstract][Full Text] [Related]
11. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.
Bagaglio S; Porrino L; Lazzarin A; Morsica G
Infection; 2010 Oct; 38(5):417-21. PubMed ID: 20533073
[TBL] [Abstract][Full Text] [Related]
13. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
[TBL] [Abstract][Full Text] [Related]
15. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
16. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
17. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
18. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
[TBL] [Abstract][Full Text] [Related]
19. Update on occult hepatitis B virus infection.
Makvandi M
World J Gastroenterol; 2016 Oct; 22(39):8720-8734. PubMed ID: 27818588
[TBL] [Abstract][Full Text] [Related]
20. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Stockdale AJ; Phillips RO; Beloukas A; Appiah LT; Chadwick D; Bhagani S; Bonnett L; Sarfo FS; Dusheiko G; Geretti AM;
Clin Infect Dis; 2015 Sep; 61(6):883-91. PubMed ID: 26021992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
